May 9, 2025 02:31 PM EDT

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Nicole DeFeudis

Editor

Iovance Biotherapeutics’ stock $IOVA dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales predictions and reported lower-than-expected sales …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Nicole DeFeudis

Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

HHS says it's pulled Covid shot guidance for healthy kids. The CDC vaccine schedule shows otherwise

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

AstraZeneca agrees to pay $51M to settle ‘pay-for-delay’ class action suit

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi